Clinics in Orthopedic Surgery • Vol. 11, No. 3, 2019 • www.ecios.org ment (PBM) has been recommended to reduce transfusion and transfusion-related complications by World Health Organization (WHO). [11] [12] [13] Based on the PBM concept, the restrictive transfusion strategy was developed. In that strategy, the patient is transfused when the level of Hb is lower than 8 g/dL or anemic symptoms are present. [14] [15] [16] [17] Intravenous supplementation of iron has been known to reduce or prevent red blood cell transfusion in patients undergoing joint arthroplasty. 18) We followed the traditional liberal strategy with the higher transfusion threshold in HFS patients until May 2009. In June 2009, we adopted the PBM of the restrictive strategy combined with intravenous iron supplementation and thereafter, we have used that concept in HFS patients. In this study, we compared the transfusion rate, amounts of transfusion, postoperative Hb level, duration of hospital stay, morbidity, and mortality between the two strategies after HFS.
METHODS
This retrospective study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB No. B-1710/427-103), which waived informed consents. We reviewed the medical records of 1,777 patients who underwent surgery due to a hip fracture (femoral neck or intertrochanteric fracture) at one tertiary referral hospital between May 2003 and June 2014 and were aged more than 60 years at the time of surgery. We excluded 13 patients who had pathologic fractures, 48 patients who had revision operations, and 82 patients who were lost to follow-up before 1 year after the operation. This left 1,634 patients, who were subjects of this study. In all patients the Hb level was measured at admission. Anemia was defined according to the criteria of the WHO 18) : a Hb level less than 12 g/dL in women and less than 13 g/dL in men. The Hb level was measured on the first postoperative day as a routine and repeatedly thereafter if considered necessary on clinical grounds.
The liberal transfusion strategy group (liberal group) included 775 patients who underwent HFS between May 2003 and May 2009. In this group, if the Hb level was below 10 g/dL within 3 days after surgery, blood was transfused as much as needed to maintain the Hb level of 10 g/dL or more.
The restrictive transfusion strategy group (restrictive group) included 859 patients who underwent HFS between June 2009 and June 2014. All patients in this group received intravenously 200 mg (maximum daily dose) of iron supplementation (Venoferrum; Vifor, Glattbrugg, Switzerland) before surgery. If the Hb level was below 8 g/dL or symptoms or signs of acute anemia (e.g., dizziness, chest pain, tachycardia, and persistent hypotension) were present, the patient received transfusion in addition to the iron supplementation before the surgery. After the surgery, the presence of anemic symptoms or signs as well as Hb level was monitored. Patients were transfused postoperatively if the anemic symptoms or signs developed or the Hb level fell below 8 g/dL within 3 postoperative days.
Except for the transfusion management strategy, all surgical procedures and postoperative cares were done in the same manner in the two groups. Basic characteristics of patients of the two groups are presented in Table 1 . Surgeons considered patient's age, presence of osteoporosis, underlying comorbidities, activity level before the injury, 19) since 2010, all patients have mechanical prophylaxis using intermittent pneumatic compression devices. 20) Only patients who have risk factors for VTE are medicated with thromboprophylaxis agents.
After discharge, patients were followed up at 6 weeks, 3 months, 6 months, 9 months, 1 year, and every year thereafter. At postoperative 6 weeks, the level of Hb was measured. We compared the perioperative blood loss (the sum of estimated blood loss during surgery and postoperative drainage), the amount of transfusion, duration of hospital stay, postoperative medical complications (myocardial infarction and cerebrovascular event), and mortality rate between the two groups. The mortality rate was evaluated at postoperative 30, 60, and 90 days. In the restrictive group, we investigated adverse reactions of intravenous iron supplementation, such as hypersensitivity and infusion site reactions.
Statistical Analysis
The Kolmogorov-Smirnov test was first used to estimate the normality, and all continuous variables showed normal distribution. We used chi-square test for categorical data and the Student t-test for continuous data. Statistical analyses were conducted with the SPSS ver. 16.0 (SPSS Inc., Chicago, IL, USA). For all other tests, a two-sided p-value < 0.05 was considered significant.
RESULTS
No adverse reaction due to intravenous iron supplementation was identified in the restrictive group. The total blood loss was less in the restrictive group than in the liberal group (349.3 ± 322.6 vs. 587.5 ± 354.6 mL, p < 0.001). Transfusion was performed in 506 patients (65.3%) in the liberal group and in 414 patients (48.2%) in the restrictive group (p < 0.001). The amount of transfused blood was less in the restrictive group than in the liberal group (342.6 ± 454.5 vs. 576.6 ± 591.8 mL, p < 0.001).
At 6 weeks after the surgery, in the restrictive group, the mean Hb was higher (11.5 vs. 10.9 g/dL, p < 0.001), and the proportion of anemia was lower (65.3% vs. 83.5%). The mean hospital stay was shorter in the restrictive group (21.5 vs. 28.8 days, p < 0.001). There was no significant difference in medical complications. The mortality at 30, 60, and 90 days were similar between the two groups ( Table 2 ).
DISCUSSION
Our study showed that the restrictive transfusion strategy (PBM) combined with preoperative intravenous iron supplementation could reduce the rate and amount of transfusion after HFS without increasing perioperative morbidity and mortality. Furthermore, postoperative Hb level at 6 weeks was higher in the restrictive group. Blood transfusions are frequently required in HFS of elderly patients. Yet, the Hb threshold at which blood transfusion is necessary remains controversial and only limited number of studies on this issue are available. 17, 21, 22) The reduced transfusion rate could be derived from the change of transfusion criteria (Hb level, from 10 g/dL to 8 g/dL). But, the perioperative morbidity and mortality did not increase in the restrictive group.
Some studies have demonstrated the effects of postoperative intravenous iron supplementation on reduced requirement of blood transfusion or on the recovery of Hb. [23] [24] [25] [26] To our understanding, the current study is the first one that evaluated the effects of restrictive transfusion strategy combined with preoperative iron supplementation. Considering the time required for erythropoiesis after iron supplementation, our results suggest that our protocol would be more useful in HFS than the restrictive strategy alone. Interestingly, the Hb level was higher at 6 weeks in patients who were given intravenous iron injection preoperatively. The use of intravenous iron supplementation has several concerns including hypersensitivity, cardiovascular events, and infusion site reaction. 27) However, a systematic review concluded that intravenous iron supplementation is not associated with increased risk of drug reactions or infections. 28) In our patients, we did not encounter any ironrelated adverse reactions.
Our study is not a randomized clinical study, but it is a retrospective study comparing with a historical control group. In addition, the efficacy of perioperative iron supplementation and restrictive strategy were already reported; [23] [24] [25] [26] 29, 30) thus, a randomized clinical trial would not be ethically justified. Although age, sex, and body mass index were similar between both groups, other factors including type of surgery such as arthroplasty might have affected the outcomes. Our blood management protocol consisting of the restrictive transfusion strategy combined with preoperative intravenous iron supplementation was effective and safe in HFS of elderly patients.
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